A cerebrospinal fluid (CSF) Alzheimer’s disease (AD) profile, that is, decreased amyloid-β1-42 (Aβ42) and increased total tau protein (t-tau) and/or phosphorylated tau at threonine-181 (p-tau),1 has been identified in a substantial number of dementia with Lewy bodies (DLB) patients, and it has been related to a more rapid cognitive decline.1 We investigated the association between AD CSF biomarkers and DLB core clinical features to better understand in vivo how AD pathology influences DLB clinical presentation. We included 171 subjects with a clinical diagnosis of probable DLB2 3 from the European DLB consortium (E-DLB). The centres involved are summarised in online supplementary table 1. Clinical examination was performed as previously reported.1 Dopamine transporter (DAT) single-photon emission CT scans (123I-FP-CIT-SPECT) were performed in 80 patients.### Supplementary data [jnnp-2019-320980supp001.pdf] CSF samples were collected at each centre according to the procedures detailed in online supplementary table 1. An AD CSF profile was defined as low Aβ42 combined with high t-tau or p-tau.1 Information about pharmacological treatments of patients were not available at each centre. Statistical analyses were performed using SPSS V.24. Association between CSF biomarkers (normal or abnormal), and each core features (present or absent), were tested with χ2 test. Associations between single CSF biomarkers and groups of subjects with different core clinical features’ number (1–4) were tested with Armitage test for trend. Local ethics committees approved the study. All patients gave their written consent for the use of their …

中文翻译：

---

CSF tau蛋白与路易氏体痴呆患者的非典型临床表现有关。

脑脊液（CSF）的阿尔茨海默氏病（AD）档案，即苏氨酸181（p-tau）的淀粉样蛋白-β1-42（Aβ42）降低和总tau蛋白（t-tau）和/或磷酸化tau增加，在许多路易体痴呆（DLB）患者中发现1，并且与认知功能下降较快有关。1我们调查了AD CSF生物标志物与DLB核心临床特征之间的关联，以更好地了解体内如何AD病理学影响DLB临床表现。我们纳入了来自欧洲DLB联盟（E-DLB）的171名可能诊断为DLB2 3的临床诊断对象。在线补充表1中汇总了所涉及的中心。如先前报道的那样进行了临床检查。在80例患者中进行了1次多巴胺转运蛋白（DAT）单光子发射CT扫描（123I-FP-CIT-SPECT）。###补充数据[jnnp-2019-320980supp001.pdf]在线补充表1中详细介绍了这些程序。AD CSF谱定义为低Aβ42与高t-tau或p-tau结合。1每个中​​心都未提供有关患者药理治疗的信息。使用SPSS V.24进行统计分析。用χ2检验对CSF生物标志物（正常或异常）与每个核心特征（存在或不存在）之间的关联进行了检验。使用Armitage检验来检验单个CSF生物标记物与具有不同核心临床特征编号（1-4）的受试者组之间的关联。当地伦理委员会批准了该研究。